Evaluate of Jiawei Xiaoyao San for Irritable Bowel Syndrome

ZHENG Fu-jie; LIU Hai-feng; LI Xin-yan; WANG Su-mei; GU Jing

doi:10.13422/j.cnki.syfjx.2015090212

您当前的位置：

首页 >

文章列表页 >

Evaluate of Jiawei Xiaoyao San for Irritable Bowel Syndrome

更新时间：2024-01-04

- Evaluate of Jiawei Xiaoyao San for Irritable Bowel Syndrome
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 21, Issue 9, Pages: 212-217(2015)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2015090212
  CLC： R259
- Published：2015
- 稿件说明：
移动端阅览
ZHENG Fu-jie, LIU Hai-feng, LI Xin-yan, et al. Evaluate of Jiawei Xiaoyao San for Irritable Bowel Syndrome[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(9): 212-217.
DOI：

ZHENG Fu-jie, LIU Hai-feng, LI Xin-yan, et al. Evaluate of Jiawei Xiaoyao San for Irritable Bowel Syndrome[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(9): 212-217. DOI： 10.13422/j.cnki.syfjx.2015090212.

摘要

目的: 系统评价加味逍遥散治疗肠易激综合征(IBS)的疗效与安全性. 方法: 计算机检索VIP

CNKI

万方

CBMdisc

收集以加味逍遥散为干预措施治疗肠易激综合征的随机对照试验

按Cochrane系统评价方法

评价纳入研究的方法学质量并提取有效数据进行Meta分析. 结果: 共纳入17个随机对照试验

包括1 542例肠易激综合征患者.Meta分析结果显示

加味逍遥散改善IBS症状及体征的总有效率优于其他治疗方法

且复发率低于对照组

比较结果显示RR(95%CI)分别为[1.31(1.24

1.38)

P <0.000 01]

[0.33(0.22

0.49)

P <0.000 01]

缺乏对加味逍遥散不良反应及长期副作用的报告. 结论: 这篇系统评价显示加味逍遥散对肠易激综合征的疗效优于其他治疗方法

但由于纳入文献质量不高

存在较大的偏倚风险

缺乏随访或随访资料不完善

不能评价加味逍遥散的远期疗效和安全性

使其对肠易激综合征临床治疗的指导意义受到限制.

Abstract

Objective: The aim of this study was to evaluate the efficacy and safety of Jiawei Xiaoyao San for irritable bowel syndrome. Method: We searched the VIP

CNKI

Wanfang and China biology medicine disc(CBMdisc) databases. Randomized controlled trials of clinical therapeutic studies on Jiawei Xiaoyao San for irritable bowel syndrome were included. The quality of included studies was evaluated and Meta-analysis was performed. Result: In this study

17 trials involving 1 542 patients were included. Meta-analysis indicated that Jiawei Xiaoyao San was lower in the recurrence rate and more effective than other drugs in improving symptoms and signs of irritable bowel syndrome. The RR value (95%CI)were[RR=0.33

95%CI(0.22

0.49)

P <0.000 01]and[RR=1.31

95%CI(1.24

1.38)

P< 0.000 01]

respectively. The most included researches did not report adverse reactions. Conclusion: Based on this review

Jiawei Xiaoyao San is effective for irritable bowel syndrome. However

the evidence is not strong enough due to the low quality of included trials. Further

large-sample and multi-center studies are needed.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and Safety of Lianhua Qingwen Preparation in Treatment of Community-acquired Pneumonia：A Systematic Review and Meta-analysis

Meta Analysis of Integrated Traditional Chinese and Western Medicine in Treatment of Chronic Liver Failure

Systematic Review and Meta-analysis of Hexue Mingmu Tablets in Treatment of Diabetic Retinopathy and Retinal Vein Obstruction

Signaling Pathways Related to Irritable Bowel Syndrome Treated by Traditional Chinese Medicine： A Review

Systematic Review of Chinese Medicine in Improving Sperm Quality in Animal Experiments Based on Structure and Function of Sertoli Cells

Related Author

HA Yanxiang

LIU Xin

KANG Shiwei

WANG Shuo

QIN Deyuan

SHU Faming

MAO Dewen

HUANG Ying

Related Institution

The Second Hospital of Hebei Medical University

Beijing Hospital of Traditional Chinese Medicine， Capital Medical University

Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine

The First Affiliated Hospital of Guangxi University of Chinese Medicine

Affiliated Hospital of Nanjing University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰